Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 14/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 12/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.49 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | KDM1A | O60341 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6848857 | 1.00 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL6848853 | 1.00 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL6851950 | 1.00 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL6851956 | 1.00 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL10968901 | 0.96 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL15823722 | 0.77 | CHRNA1 (0.35) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL10966310 | 0.76 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL11024795 | 0.76 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL11024403 | 0.76 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 | |
| SCHEMBL11351044 | 0.76 | SLC6A4 (0.52) | SLC6A4SLC6A2SLC6A3OPRM1SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780891-B2 | MODULATE OPIATE RECEPTORS; CENTRAL NERVOUS SYSTEM DISORDERS | SEPRACOR INC. | 2004-08-24 | — | — | US | disclosed |
| US-20030171440-A1 | Tramadol analogs and uses thereof | SEPRACOR INC. | 2003-09-11 | — | — | US | disclosed |
| WO-2003048113-A1 | TRAMADOL ANALOGS AND USES THEREOF | SEPRACOR INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-0061899-B1 | MORPHOLINES | JOHN WYETH & BROTHER LIMITED (GB) | 1985-03-20 | — | — | EP | disclosed |
| US-4387097-A | Morpholines | JOHN WYETH AND BROTHER LIMITED (GB) | 1983-06-07 | — | — | US | disclosed |
| EP-0061899-A1 | Morpholines | JOHN WYETH & BROTHER LIMITED (GB) | 1982-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171440-A1 | Tramadol analogs and uses thereof | OPRD1, OPRK1, OPRM1 | SLC6A4 56/4885SLC6A2 81/4885SLC6A3 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.